Evidence map›Paper›PMID 19723641›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009

Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008.

Paul Okunieff, Lisa A Kachnic, Louis S Constine, Clifton D Fuller, Laurie E Gaspar, Daniel F Hayes, Jean Hooks, Clifton Ling, Frank L Meyskens, Philip A Philip and 8 more

Open access · greenAbstract readConference Proceedings
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. AnClinical and translational radiation oncology · 2019
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Paul OkunieffUniversity of Rochester Medical Center, Rochester, New York 14642, USA. paul_okunieff@urmc.rochester.edu
Lisa A Kachnic
Louis S Constine
Clifton D Fuller
Laurie E Gaspar
Daniel F Hayes
Jean Hooks
Clifton Ling
Frank L Meyskens
Philip A Philip
David Raben
Stephen R Smalley
Gregory P Swanson
Beverly A Teicher
Charles R Thomas
Bhadrasain Vikram
Michael J Zelefsky
Laurence H Baker
Varian Medical Systems (United States) · USUniversity of Michigan–Ann Arbor · USUniversity Medical Center · USUniversity of Colorado Denver · USUniversity of Rochester Medical Center · USThe Barbara Ann Karmanos Cancer Institute · US

Funding

SWOG - Foreign Accrual under UMiU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BLANKE, CHARLES D. · 1985 to 2013
$141.3M
SOUTHWEST ONCOLOGY GROUP--STATISTICAL CENTERU10CA038926 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEBLANC, MICHAEL L. · 1985 to 2013
$69.8M
Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Christine Hui · 1994 to 2026
$57.9M
SOUTHWEST ONCOLOGY GROUPU10CA011083 · NCI · UNIVERSITY OF ROCHESTER · PI FRIEDBERG, JONATHAN W · 1985 to 2013
$5.5M
Southwest Oncology Group U10 Member SiteU10CA014028 · NCI · WAYNE STATE UNIVERSITY · PI FLAHERTY, LAWRENCE E · 1985 to 2013
$4.1M
SOUTHWEST ONCOLOGY GROUPU10CA027057 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHOTT, ANNE F · 1985 to 2013
$4.0M
UNIVERSITY OF COLORADO-SOUTHWEST ONCOLOGY GROUPU10CA042777 · NCI · UNIVERSITY OF COLORADO DENVER · PI ELIAS, ANTHONY D · 1988 to 2013
$3.2M
SOUTHWEST ONCOLOGY GROUPU10CA022433 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI WEISS, GEOFFREY R. · 1985 to 2004
$1.3M
SOUTHWEST ONCOLOGY GROUPU10CA046113 · NCI · OREGON HEALTH AND SCIENCE UNIVERSITY · PI NICHOLS, CRAIG R · 1988 to 2003
$572k
SOUTHWEST ONCOLOGY GROUPU10CA058723 · NCI · UNIVERSITY OF CALIFORNIA IRVINE · PI MEYSKENS, FRANK LOUIS · 1993 to 1997
–
NCI NIH HHS CA11083NCI NIH HHS CA14028NCI NIH HHS CA22433NCI NIH HHS CA42777NCI NIH HHS CA46113NCI NIH HHS CA58723NCI NIH HHS CA76448NCI NIH HHS N01 CA027057NCI NIH HHS N01 CA032102NCI NIH HHS N01 CA038926NCI NIH HHS P30 CA062203NCI NIH HHS U10 CA011083NCI NIH HHS U10 CA014028NCI NIH HHS U10 CA022433NCI NIH HHS U10 CA027057NCI NIH HHS U10 CA032102NCI NIH HHS U10 CA038926NCI NIH HHS U10 CA042777NCI NIH HHS U10 CA046113
6 · The paper itself

Abstract

Strategic planning for the Radiation Therapy Committee of the Southwest Oncology Group (SWOG) is comprehensively evaluated every six years in an effort to maintain a current and relevant scientific focus, and to provide a standard platform for future development of protocol concepts. Participants in the 2008 Strategic Planning Workshop included clinical trial experts from multiple specialties, industry representatives from both pharmaceuticals and equipment manufacturers, and basic scientists. High-priority research areas such as image-guided radiation therapy for control of limited metastatic disease, analysis of biomarkers for treatment response and late toxicity, assessment of novel agents in combination with radiation, standardization of radiation target delineation, and the assessment of new imaging techniques to individualize cancer therapy, were discussed. Research priorities included clinical study designs featuring translational end points that identify patients most likely to benefit from combined modality therapy; intervention including combination radiation with standard chemotherapy; radiation with radiosensitizing molecular-targeted therapies; and stereotactic radiation for treatment of patients with regard to asymptomatic metastasis and radiation-induced tumor autoimmunity. The Committee concluded that the future research opportunities are among the most exciting to have developed in the last decade, and work is in progress to embark on these plans.

Indexed as

Antineoplastic AgentsBiomedical ResearchClinical Trials as TopicCombined Modality TherapyFemaleHumansNeoplasmsQuality Assurance, Health CareRadiation OncologyRadiotherapy DosageRadiotherapy Planning, Computer-AssistedTranslational Research, BiomedicalAntineoplastic Agents

Identifiers

PMID19723641
PMCPMC2978526
OpenAlexW2102685417

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.